A phase 1 dose escalation study of ARQ 197 in adult patients with metastatic solid tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2009
At a glance
- Drugs Tivantinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 01 Jun 2009 A total of 74 patients have been treated in this trial and final results were presented at ASCO, according to an ArQule media release.
- 01 Jun 2009 Status changed from recruiting to completed. Final results were presented at ASCO.
- 26 May 2009 Additional lead trial investigator (Makhail T) identified as reported by ClinicalTrials.gov.